Responding to sustained growth in demand for our Regulatory Services, Boyds has appointed Dr Victoria Marsh, a specialist in molecular biology and protein biochemistry, as Director of Regulatory Affairs in our Regulatory Affairs team.
Victoria has extensive regulatory experience across the full product lifecycle from Phase I clinical trials through to licence maintenance for marketed products. She has worked with and for companies developing new chemical entities, biotechnology, gene therapy and orphan medicinal products.
As Boyds’ Director of Regulatory Affairs, Victoria will provide regulatory advice and support throughout the full product lifecycle and across a range of therapeutic areas for advanced therapy medicinal products (ATMPs), biological and new chemical entities.
Prior to joining Boyds, Victoria spent nine years working at MedImunne Limited / AstraZeneca, where her responsibilities included being global regulatory lead for a late stage MEK inhibitor for the orphan indication neurofibromatosis type 1 and early phase CD40 agonist and plasmid DNA vaccines. She was also European regulatory lead for an irreversible EGFR-TKI in advanced NSCLC and for several products within Respiratory, Inflammation and Autoimmune disease areas.
She also worked as part of the Human Genome Project at the Sanger Centre and in 2005 obtained a PhD in Biochemistry from Cambridge University.
Of joining Boyds, Victoria says:
“Working at Boyds gives me the opportunity to support the development of unique biological products and ATMPs across a range of therapeutic areas. I’m thrilled to take on my new role as Director of Regulatory Affairs and look forward to working with a talented team of regulatory affairs specialists.”
Professor Alan Boyd adds:
“With over 20 years’ experience in Regulatory Affairs and R&D, we are thrilled to have someone of such a high calibre as Victoria joining us at Boyds. As our Regulatory Affairs team continues on its strong upward trajectory of growth, we look forward to adding Victoria’s specialist expertise to our service offering.”